title: Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers.
authors.forename: Markus
authors.initials: M
authors.lastname: Hinder
authors.forename: Anne
authors.initials: A
authors.lastname: Paccaly
authors.forename: Annke
authors.initials: A
authors.lastname: Frick
authors.forename: Umesh
authors.initials: U
authors.lastname: Shukla
authors.forename: Kelly
authors.initials: K
authors.lastname: Simcox
authors.forename: Barry
authors.initials: B
authors.lastname: Miller
authors.forename: Alexander
authors.initials: A
authors.lastname: Gebauer
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D003497:Cyclic N-Oxides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D065427:Factor Xa Inhibitors; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D015415:Biomarkers; D003497:Cyclic N-Oxides; D065427:Factor Xa Inhibitors; D011725:Pyridines; D014443:Tyrosine; D000077466:Tirofiban; C435830:otamixaban